Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

SAR-707 reveals limitations of acyl-CoA desaturase inhibition in metabolic disorders

Oct. 1, 2010

Elixir Pharmaceuticals claims new ghrelin receptor modulators

Sep. 30, 2010

KAI-4169 enters phase Ib trial for secondary hyperparathyroidism in ESRD

Sep. 30, 2010

CONQUER trial reveals benefits of phentermine/topiramate combination in obesity

Sep. 30, 2010

Clinical data presented on DiaPep-277 in type 1 diabetes

Sep. 30, 2010

Nycomed submits European filing for marketing approval of EX-101

Sep. 29, 2010

Imeglimin shows promise in phase II trials in type 2 diabetes

Sep. 29, 2010

Phase II data on MK-0941 cast doubt on suitability for treatment of diabetes

Sep. 29, 2010

FDA accepts Bionovo's manufacturing plan for Menerba

Sep. 28, 2010

Phenex Pharma receives financing for FXR and RORgt R&D programs

Sep. 28, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...